Terlipressin regulatory status
Current status of Terlipressin in the United States: FDA approved. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Terlipressin?
Regulatory: FDA approvedWADA: WADA status unclearVerified: Verified Sep 30, 2026
- FDA and compounding
- FDA approved prescription drug (Terlivaz, approved September 14, 2022 for hepatorenal syndrome with rapid reduction in kidney function), administered intravenously in hospital. Widely used in Europe for decades before US approval. Commercially available, so not eligible for routine compounding and not on any 503A bulks list. Not a research chemical.
- WADA
- WADA status unclear
- Access path
- Hospital administration under a hepatologist or intensivist for a confirmed diagnosis of hepatorenal syndrome.
- Not available through retail pharmacies, compounding pharmacies, or telehealth.
Full Terlipressin page: evidence, dosing in the literature, and sources
How has the status of Terlipressin changed over time?
- FDA
FDA approves Terlivaz (terlipressin) for hepatorenal syndrome
FDA approved terlipressin injection (Terlivaz), a vasopressin analog, to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
Regulatory: FDA approvedSource: Drugs@FDA: Terlivaz (terlipressin) NDA 022231
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Terlipressin and the source of each dated event.
- [1]Drugs@FDA: Terlivaz (terlipressin) NDA 022231FDA, 2022
- [2]FDA prescribing information for Terlivaz (terlipressin) for injection, via DailyMedFDA, 2026
- [3]WADA Prohibited ListWADA, 2026